Foundation Medicine to Share 10 Abstracts at AACR23 Demonstrating the Unique Capabilities of Its Molecular Profiling Tests to Advance Precision Cancer Care

2023-04-05
Business Wire
AACR会议临床研究
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced that the company and its collaborators will present a total of 10 studies at the 2023 American Association for Cancer Research (AACR) Annual Meeting from April 14-19 in Orlando, Florida.
'Our experience sequencing over one million patient samples has allowed us to continuously improve our approach and have high confidence in the genomic abnormalities we detect and the results we deliver'
Presentation highlights:
Over the past several years, there has been great progress in the ability to identify shed pieces of tumor, called circulating tumor DNA (ctDNA), within a cancer patient’s blood. In partnership with South Australian Immunogenomics Cancer Institute, Saint Bartholomew’s Hospital and Genentech, Foundation Medicine researchers used its novel methylation sequencing research platform to detect ctDNA as a prognostic biomarker in overall survival for patients with metastatic castrate resistant prostate cancer (mCRPC). Results from ctDNA evaluation as early as 6 weeks post treatment initiation were comparable to prostate specific antigen (PSA) response in second line mCRPC, providing an early non-invasive readout that is independent of PSA for monitoring therapy response in late stage mCRPC.
Historical barriers in the study of small cell lung cancer (SCLC) include the relative lack of human tumors studied, limited real-world data, and the lack of access to longitudinal samples to understand tumor evolution. In partnership with Stanford University and Vanderbilt University Medical Center, Foundation Medicine researchers conducted what is believed to be the largest SCLC study known to date to provide an improved understanding of genetic subtypes in SCLC, including patient ancestry and biopsy site-specific patterns, and better inform mechanisms of transformation to SCLC from non-small cell lung cancer that may further guide the development of personalized therapies for subsets of patients with this fatal tumor.
“Our experience sequencing over one million patient samples has allowed us to continuously improve our approach and have high confidence in the genomic abnormalities we detect and the results we deliver,” said Priti Hegde, PhD, chief scientific officer at Foundation Medicine. “We are committed to bringing high-quality, differentiated and sustainable solutions, like options for sensitive ctDNA monitoring, to our physician and researcher partners so that they can provide all patients with the best treatment options for their unique cancers.”
The following is a list of abstracts that will be presented at the meeting. To access all abstracts being presented at AACR, please visit AACR.org.
Follow Foundation Medicine on Twitter and LinkedIn for more updates from #AACR23 and visit us in person at Booth #3053.
Abstract #
Title
Collaborator
Product
Posters
305
Sunday, April 16
1:30 – 5:00 PM
POLE variant detection and classification is critical for identifying patients who may benefit from immunotherapy
FoundationOne®CDx and FoundationOne®Liquid CDx
228
Sunday, April 16
1:30 – 5:00 PM
Recurrent mitochondrial mutations in thyroid cancer
FoundationOne®CDx
931
Sunday, April 16
1:30 – 5:00 PM
Comprehensive analysis of 3,600 small cell lung cancer cases reveals rare genetic subtypes and multiple mechanisms of histological transformation
FoundationOne®CDx,
Foundation Medicine & Flatiron Health’s Joint Clinico-Genomic Database
933
Sunday, April 16
1:30 – 5:00 PM
The landscape of treatment patterns in non-small cell lung cancer post EGFR TKI treatment described by real world data from 428 patients
Flatiron Health, One Oncology
Foundation Medicine & Flatiron Health’s Joint Clinico-Genomic Database
938
Sunday, April 16
1:30 – 5:00 PM
Outcomes of Molecular Tumor Board recommendations for cancer patients with progression on standard of care therapies in Saudi Arabia
FoundationOne®CDx
966
Sunday, April 16
1:30 – 5:00 PM
Exploration of a novel HRD signature (HRDsig) as a biomarker for rucaparib benefit in ARIEL2
FoundationOne®CDx
305
Monday, April 17
9:00 a.m. – 12:30 p.m.
Co-occurrence of alterations impacting telomere elongation
FoundationOne®CDx
2289
Monday, April 17
9:00 a.m. – 12:30 p.m.
Predicting tumor somatic vs versus clonal hematopoiesis (CH) origin for short variants (SV) with FoundationOne®Liquid CDx assay
FoundationOne®Liquid CDx
3362
Monday, April 17
1:30 – 5:00 p.m.
Evaluation of circulating tumor DNA kinetics as a prognostic biomarker for overall survival in metastatic castrate resistant prostate cancer using a novel methylation sequencing research assay
South Australian Immunogenomics Cancer Institute, Genentech, St. Bartholomew’s Hospital
Research methylation assay
3395
Monday, April 17
1:30 – 5:00 p.m.
Clinical Impact of FGFR inhibitors on FGFR2 Fusion Positive Pancreatic Cancer
FoundationOne®CDx
About Foundation Medicine: Your Essential Partner in Cancer Care
Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on Twitter and LinkedIn.
Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.
Source: Foundation Medicine
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。